Status: Recruiting
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
This is a Phase 3, Open-Label, Multicenter, Randomised, Controlled Study designed to compare RC48-ADC in Combination With JS001 to Chemotherapy Alone in Previously Untreated HER2-Expressing Unresectable Locally Advanced or Metastatic Urothelial Carcinoma.
Participants needed: 452
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: RemeGen Co., Ltd.Updated: Dec 18, 2023Locations: 2
Eligibility criteria
Expected survival ≥12 weeks. [+5]
Known hypersensitivity to RC48-ADC or Toripalimab or any of its components. [+9]